Mnemo Therapeutics
Armelle Bohineust has been working in the scientific field since 2010. Armelle began as an Étudiant doctorant at Institut Curie in 2010, then moved on to Institut Pasteur as a Chercheur postdoctoral in 2014. Armelle then joined Institut de Recherche Saint-Louis (IRSL) in 2020 as a Chercheur postdoctoral, and is currently working as a Scientist onco-immuno at Mnemo Therapeutics since 2022.
Armelle Bohineust completed their Doctorate in Immunology from Université Paris Cité in 2013, followed by a Master in Immunology from the same university in 2009.
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.